Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes

In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites.

[1]  K. Hao,et al.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. , 2010, Genome research.

[2]  Steven N. Hart,et al.  A Comparison of Whole Genome Gene Expression Profiles of HepaRG Cells and HepG2 Cells to Primary Human Hepatocytes and Human Liver Tissues , 2010, Drug Metabolism and Disposition.

[3]  Christina Magkoufopoulou,et al.  Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  O. Herbarth,et al.  Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the human hepatoma derived cell line HepG2. , 2010, Toxicology and applied pharmacology.

[5]  V. Tan,et al.  Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. , 2009, Bioorganic & medicinal chemistry.

[6]  T. Tsou,et al.  The inhibition effect of 2,3,7,8-tetrachlorinated dibenzo-p-dioxin-induced aryl hydrocarbon receptor activation in human hepatoma cells with the treatment of cadmium chloride. , 2009, Journal of hazardous materials.

[7]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[8]  R. Walsky,et al.  In vitro cytochrome P450 inhibition and induction. , 2008, Current drug metabolism.

[9]  Wei Duan,et al.  Clinical pharmacogenetics and potential application in personalized medicine. , 2008, Current drug metabolism.

[10]  Scott A. Rifkin,et al.  Revealing the architecture of gene regulation: the promise of eQTL studies. , 2008, Trends in genetics : TIG.

[11]  Sang Chung,et al.  New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process , 2008, Journal of clinical pharmacology.

[12]  J. Xu,et al.  In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  John D. Storey,et al.  Mapping the Genetic Architecture of Gene Expression in Human Liver , 2008, PLoS biology.

[14]  W. Schoonen,et al.  Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[15]  N. Hewitt,et al.  Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro–in vivo correlations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  R. Riley,et al.  The pivotal role of hepatocytes in drug discovery. , 2007, Chemico-biological interactions.

[17]  Hayley S. Brown,et al.  Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.

[18]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[19]  C. Tohyama,et al.  Lack of CYP1A1 expression is involved in unresponsiveness of the human hepatoma cell line SK-HEP-1 to dioxin. , 2005, Toxicology letters.

[20]  V. Mersch-Sundermann,et al.  Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. , 2004, Toxicology.

[21]  U. Leuschner,et al.  Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid. , 2004, Biochimica et biophysica acta.

[22]  R. Costa,et al.  Transcription factors in liver development, differentiation, and regeneration , 2003, Hepatology.

[23]  Frank Stahl,et al.  Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J V Castell,et al.  Human hepatocytes as a tool for studying toxicity and drug metabolism. , 2003, Current drug metabolism.

[25]  Jos H Beijnen,et al.  An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. , 2003, Toxicology and applied pharmacology.

[26]  H. McLeod,et al.  Genetic basis of drug metabolism. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  M. T. Donato,et al.  Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. , 2001, Archives of biochemistry and biophysics.

[28]  E L LeCluyse,et al.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  V. Zachar,et al.  Quantitative Gene Expression Profiles of Human Liver-Derived Cell Lines Exposed to Moderate Hypoxia , 2001, Cellular Physiology and Biochemistry.

[30]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[31]  P. Watkins,et al.  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Castell,et al.  Re‐expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells , 1998 .

[33]  H. Norppa Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. , 1997, Environmental health perspectives.

[34]  S. Cereghini Liver‐enriched transcription factors and hepatocyte differentiation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  A. Pfeifer,et al.  Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Grant,et al.  The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line , 1988, FEBS letters.

[37]  J V Castell,et al.  Cell lines: a tool for in vitro drug metabolism studies. , 2008, Current drug metabolism.

[38]  S. Imaoka,et al.  Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. , 2008, Journal of pharmacological sciences.

[39]  J. Castell,et al.  Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. , 1998, FEBS letters.

[40]  S. Strom,et al.  Use of human hepatocytes to study P450 gene induction. , 1996, Methods in enzymology.